May 18, 2022
Four patients present with previously undiagnosed conditions.
May 17, 2022
The company, formerly known as Clover Therapeutics, intends to use the funding to advance two lead drug candidates that target molecularly-defined AMD patient subtypes.
May 12, 2022
The company's technology allows for ECPs to detect, monitor, and treat AMD 3 years before clinical diagnosis.
A look at the latest developments in retinal disease, including clinical trials and advanced therapies.
May 10, 2022
Oxurion NV finds insufficient evidence of efficacy on key clinical endpoints for THR-687 in Part A of the INTEGRAL phase 2 trial; focus will now turn to an alternative candidate and trial.
May 05, 2022
New detailed, longer-term findings were presented at the 2022 ARVO meeting.
April 27, 2022
Diagnosis highlights overlooked treatments for this disease
April 25, 2022
Investigators report a correlation between the risk of 5-letter visual acuity (VA) loss at 24 months for eyes with clinically significant diabetic macular edema (CSDME) and good VA initially treated and eyes that were initially observed in routine clinical practice.
April 21, 2022
Gifted by philanthropist James Grosfeld, the money will fund the launching of a pioneering research initiative as one of the largest investments of resources in the United States.
April 07, 2022
Elevatum was created as a phase 4, multicenter, open-label, single-arm trial to specifically study Vabysmo (faricimab-svoa) in these underrepresented populations.
Eyeglasses target myopia prevention with artificial light
Research to Prevent Blindness, Aerie partner on glaucoma research grant
Character Biosciences raises $18 million in funding for AMD therapy development
COVID-19: Increased incidence of RVOs post-diagnosis
